Logo image of SLNO

SOLENO THERAPEUTICS INC (SLNO) Stock Fundamental Analysis

NASDAQ:SLNO - Nasdaq - US8342033094 - Common Stock - Currency: USD

86.02  -0.95 (-1.09%)

After market: 85.1 -0.92 (-1.07%)

Fundamental Rating

2

Taking everything into account, SLNO scores 2 out of 10 in our fundamental rating. SLNO was compared to 556 industry peers in the Biotechnology industry. While SLNO seems to be doing ok healthwise, there are quite some concerns on its profitability. SLNO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SLNO had negative earnings in the past year.
SLNO had a negative operating cash flow in the past year.
SLNO had negative earnings in each of the past 5 years.
In the past 5 years SLNO always reported negative operating cash flow.
SLNO Yearly Net Income VS EBIT VS OCF VS FCFSLNO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

SLNO has a Return On Assets of -62.58%. This is in the lower half of the industry: SLNO underperforms 60.25% of its industry peers.
SLNO has a Return On Equity (-85.78%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -62.58%
ROE -85.78%
ROIC N/A
ROA(3y)-55.18%
ROA(5y)-58.08%
ROE(3y)-109.69%
ROE(5y)-111.38%
ROIC(3y)N/A
ROIC(5y)N/A
SLNO Yearly ROA, ROE, ROICSLNO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

SLNO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLNO Yearly Profit, Operating, Gross MarginsSLNO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for SLNO has been increased compared to 1 year ago.
Compared to 5 years ago, SLNO has more shares outstanding
Compared to 1 year ago, SLNO has a worse debt to assets ratio.
SLNO Yearly Shares OutstandingSLNO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
SLNO Yearly Total Debt VS Total AssetsSLNO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

SLNO has an Altman-Z score of 27.32. This indicates that SLNO is financially healthy and has little risk of bankruptcy at the moment.
SLNO's Altman-Z score of 27.32 is amongst the best of the industry. SLNO outperforms 95.86% of its industry peers.
SLNO has a Debt/Equity ratio of 0.22. This is a healthy value indicating a solid balance between debt and equity.
SLNO has a worse Debt to Equity ratio (0.22) than 70.32% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF N/A
Altman-Z 27.32
ROIC/WACCN/A
WACCN/A
SLNO Yearly LT Debt VS Equity VS FCFSLNO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 19.31 indicates that SLNO has no problem at all paying its short term obligations.
SLNO has a Current ratio of 19.31. This is amongst the best in the industry. SLNO outperforms 92.63% of its industry peers.
SLNO has a Quick Ratio of 19.31. This indicates that SLNO is financially healthy and has no problem in meeting its short term obligations.
SLNO has a better Quick ratio (19.31) than 92.63% of its industry peers.
Industry RankSector Rank
Current Ratio 19.31
Quick Ratio 19.31
SLNO Yearly Current Assets VS Current LiabilitesSLNO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for SLNO have decreased strongly by -72.39% in the last year.
EPS 1Y (TTM)-72.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-61.02%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

SLNO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 48.30% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y24.79%
EPS Next 2Y51.35%
EPS Next 3Y48.3%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SLNO Yearly Revenue VS EstimatesSLNO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2025 2026 2027 100M 200M 300M 400M 500M
SLNO Yearly EPS VS EstimatesSLNO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -50 -100 -150

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SLNO. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 69.48, the valuation of SLNO can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of SLNO indicates a rather cheap valuation: SLNO is cheaper than 88.85% of the companies listed in the same industry.
SLNO's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 36.71.
Industry RankSector Rank
PE N/A
Fwd PE 69.48
SLNO Price Earnings VS Forward Price EarningsSLNO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLNO Per share dataSLNO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as SLNO's earnings are expected to grow with 48.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y51.35%
EPS Next 3Y48.3%

More info and screens

0

5. Dividend

5.1 Amount

SLNO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SOLENO THERAPEUTICS INC

NASDAQ:SLNO (7/22/2025, 8:00:02 PM)

After market: 85.1 -0.92 (-1.07%)

86.02

-0.95 (-1.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners107.29%
Inst Owner Change-0.33%
Ins Owners1.46%
Ins Owner Change-9.61%
Market Cap4.33B
Analysts86.25
Price Target116.28 (35.18%)
Short Float %11.3%
Short Ratio5.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-4.19%
Min EPS beat(2)-7.96%
Max EPS beat(2)-0.42%
EPS beat(4)1
Avg EPS beat(4)-47.06%
Min EPS beat(4)-186.49%
Max EPS beat(4)6.6%
EPS beat(8)2
Avg EPS beat(8)-40.15%
EPS beat(12)5
Avg EPS beat(12)-24.27%
EPS beat(16)7
Avg EPS beat(16)-16%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.88%
PT rev (3m)18.2%
EPS NQ rev (1m)2.36%
EPS NQ rev (3m)-18.75%
EPS NY rev (1m)2.62%
EPS NY rev (3m)-7.84%
Revenue NQ rev (1m)3.62%
Revenue NQ rev (3m)40.08%
Revenue NY rev (1m)3.1%
Revenue NY rev (3m)34.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 69.48
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 18.68
P/tB 19.21
EV/EBITDA N/A
EPS(TTM)-4.62
EYN/A
EPS(NY)1.24
Fwd EY1.44%
FCF(TTM)-1.77
FCFYN/A
OCF(TTM)-1.77
OCFYN/A
SpS0
BVpS4.6
TBVpS4.48
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -62.58%
ROE -85.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.18%
ROA(5y)-58.08%
ROE(3y)-109.69%
ROE(5y)-111.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.31
Quick Ratio 19.31
Altman-Z 27.32
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)3.86%
Cap/Depr(5y)2.62%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-72.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-61.02%
EPS Next Y24.79%
EPS Next 2Y51.35%
EPS Next 3Y48.3%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-275.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-321.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-320.8%
OCF growth 3YN/A
OCF growth 5YN/A